Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brachytherapy seeds work on prostate cancer:

This article was originally published in Clinica

Executive Summary

Brachytherapy using Theragenics' radioactive seed implants performed as well as or better than traditional treatments for prostate cancer such as radical prostatectomy and external beam radiation, according to a nine-year US study. Some 83.5% of the 230 stage I and II patients treated with the company's TheraSeed - palladium 103 - implants were cancer-free at nine years, researchers from the Seattle Prostate Institute in Washington reported in the March issue of the International Journal of Radiation Oncology, Biology and Physics. Only 3% of patients experienced prostate cancer recurrence, said Theragenics of Buford, Georgia.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT075859

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel